Want to see PSNL full AI Analyst Report?
Revenue by Segment
Breaks down revenue across Personalis’ business lines (for example sequencing services, clinical assays, and biopharma partnerships), revealing which activities drive growth, margins, and recurring income. Highlights dependence on large customers or one-off projects versus scalable, repeatable contracts and shows whether the company is moving toward higher-value clinical products that can boost long-term profitability and reduce revenue volatility.Personalis is mid-transition: legacy enterprise revenue has materially declined while Pharma Tests & Services remains the backbone but is lumpy, reflecting project timing. Clinical Diagnostic started from near zero and is accelerating in volume but still represents a small dollar slice today; management is explicitly trading near-term margins and higher cash burn to scale Clinical reimbursement and MRD commercial traction. 2026 guidance targets meaningful Clinical and strategic revenue growth ($10–11M Clinical; $30–32M strategic), implying revenue mix and margin improvement only if reimbursement and biopharma demand continue to materialize.
Date | Other | Pharma Tests and Services | Enterprise Sales | Population Sequencing | Clinical Diagnostic |
|---|---|---|---|---|---|
Jun 30, 2026 | $27.00K | $16.79M | $0.00 | $3.00M | $2.54M |
Mar 31, 2026 | $424.00K | $10.72M | $393.00K | $2.50M | $1.43M |
Dec 31, 2025 | $1.12M | $10.90M | $456.00K | $4.01M | $857.00K |
Sep 30, 2025 | $90.00K | $13.14M | $650.00K | $234.00K | $384.00K |
Jun 30, 2025 | $88.00K | $11.02M | $2.31M | $3.31M | $469.00K |
Mar 31, 2025 | $25.00K | $13.59M | $2.46M | $4.21M | $308.00K |
Dec 31, 2024 | $3.00K | $12.23M | $4.17M | $219.00K | $176.00K |
Sep 30, 2024 | $45.00K | $15.70M | $5.26M | $4.43M | $271.00K |
Jun 30, 2024 | $28.00K | $13.20M | $7.96M | $1.28M | $117.00K |
Mar 31, 2024 | $46.00K | $9.81M | $7.97M | $1.50M | $195.00K |